Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- CEO
- Nima Farzan
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 66
- Beta
- 0.00
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
LTGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
57+88.89%Social Signal Score
Mentions (5)
- Newsdefenseworld.net·15d ago·Neutral
Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company's pipeline of non-opioid pain treatment programs
View source ↗ - Newsglobenewswire.com·80d ago·Negative
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acu
View source ↗ - News247wallst.com·101d ago·Neutral
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.
View source ↗
Earnings
Typical surprise -4374.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Sep 3$-27.59 vs $-0.62miss
Estimates and results for LTGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LTGO officers and directors.
- Bought
- $5.0m
- Sold
- —
2 trades
0 trades
- Foresite Capital Management V, Llcbought
- Tananbaum James B.bought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LTGO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
